AVZO-023 + AVZO-021 + fulvestrant

**AVZO-023 + AVZO-021 + fulvestrant** is an investigational combination therapy under evaluation primarily for advanced or metastatic hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer and select other advanced solid tumors. - **AVZO-023** is an oral, potent, and selective inhibitor of cyclin-dependent kinase 4 (CDK4). - **AVZO-021** is an oral, potent, and selective inhibitor of cyclin-dependent kinase 2 (CDK2). - **Fulvestrant** is a selective estrogen receptor degrader (SERD) acting as an antagonist of the estrogen receptor. The combination is designed to address resistance mechanisms in HR+/HER2- breast cancer by targeting cell cycle proteins (CDK4/6, CDK2) alongside hormonal blockade, aiming for improved anti-tumor efficacy and minimized toxicity. Avenzo Therapeutics has exercised exclusive global development rights for AVZO-023 (excluding Greater China) from Allorion Therapeutics and is conducting multi-arm Phase 1/2 trials for various combination regimens including this triplet[1][3][5][9].

Other names

ARTS-023ARTS023ARTS 023